Leqvio Microdosing Protocols: What the Evidence Actually Shows

What Is Inclisiran and How Does Its Dosing Work?

Inclisiran is a small interfering RNA (siRNA) that silences the gene encoding PCSK9 inside hepatocytes. By stopping PCSK9 production at the mRNA level rather than neutralizing circulating protein the way monoclonal antibodies do, it achieves durable LDL-C lowering with only two injections per year after an initial loading phase. The approved 284 mg dose was selected in Phase II to balance maximal silencing duration against the tolerability profile.

The Standard Three-Shot Loading Schedule

The FDA-approved schedule places the first injection on day 1, a second at day 90 (month 3), and then maintenance injections every 180 days. This front-loaded design compensates for the time required for siRNA to accumulate sufficient hepatic silencing. Skipping or shortening the day-90 dose leaves patients in a trough where PCSK9 mRNA recovery begins before the maintenance phase takes over.

Why the 284 mg Dose Was Chosen

Phase II ORION-1 (N=501) tested doses from 100 mg to 500 mg across single and double-dose regimens [1]. The 300 mg two-dose arm (closest to the approved 284 mg protocol) produced the most favorable duration-to-tolerability ratio at 12 months, guiding the Phase III dose selection. No sub-100 mg arm in ORION-1 achieved LDL-C reductions exceeding 30% at the 6-month mark, which is the threshold most guidelines use to define clinically meaningful PCSK9 inhibition in high-risk patients.

ORION-10 and ORION-11: The Phase III Evidence Base

ORION-10 and ORION-11 are the twin randomized controlled trials published in the New England Journal of Medicine in 2020 that established the approved regimen as the standard of care [2].

ORION-10 Design and Results

ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) who were already on maximally tolerated statin therapy. Participants received inclisiran 284 mg or placebo at days 1, 90, 270, and 450. At day 510, the inclisiran group achieved a time-averaged LDL-C reduction of 52.3% versus placebo (P<0.001). Injection-site reactions occurred in 2.6% of the inclisiran group and 0.9% of placebo recipients, all rated mild-to-moderate.

ORION-11 Design and Results

ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents, including heterozygous familial hypercholesterolemia (HeFH). The time-averaged LDL-C reduction at day 510 was 49.9% versus placebo (P<0.001) [2]. Pooled across both trials, 81% of inclisiran-treated patients reached their guideline-recommended LDL-C target of <70 mg/dL by day 510, compared with 18% in the placebo arms.

What the Trials Did Not Test

Neither ORION-10 nor ORION-11 included a reduced-dose arm, an extended-interval arm beyond 6 months, or any dose-titration protocol. The trials were designed to confirm the Phase II-selected regimen, not to explore the lower boundary of efficacy. This gap in the evidence base is exactly why "microdosing" discussions in inclisiran are largely theoretical at this stage.

Does a Microdosing Protocol for Inclisiran Exist?

The short answer is no. As of early 2025, no peer-reviewed Phase II or Phase III trial has tested inclisiran at doses below 100 mg in adults with ASCVD or HeFH. The term "microdosing" in the pharmacology literature typically refers to sub-pharmacological doses (<1/100th of the therapeutic dose) used for pharmacokinetic study under FDA exploratory IND guidance. Inclisiran at those concentrations has not been formally studied in registered clinical trials.

What Clinicians Mean When They Ask About Microdosing

In practice, when physicians ask about inclisiran microdosing they are usually asking one of three different questions:

1. Can the 284 mg dose be reduced for patients who achieve very low LDL-C (below 40 mg/dL) to avoid excessive lowering?
2. Can dosing intervals be extended beyond 6 months for cost or adherence reasons?
3. Can a lower dose be used in patients with hepatic impairment or low body weight?

Each question has a distinct evidence-based answer, and none of them currently have an approved dose-reduction pathway.

LDL-C Below 40 mg/dL: Is Dose Reduction Warranted?

ACC/AHA 2022 guidelines acknowledge that very low LDL-C levels (below 20 mg/dL) achieved through PCSK9 inhibition have not been associated with clear harm in cardiovascular outcomes trials, though long-term data beyond 5 years remain limited [3]. The FOURIER trial of evolocumab (a monoclonal PCSK9 antibody, not inclisiran) found no safety signal at median achieved LDL-C of 30 mg/dL across 27,564 patients [4]. Extrapolating that safety data to a proposed inclisiran dose reduction is not scientifically straightforward because the mechanisms and pharmacokinetics differ substantially.

Inclisiran's silencing effect cannot be titrated like a small molecule. Once the siRNA is incorporated into the RNA-induced silencing complex (RISC) inside hepatocytes, the effect persists until natural mRNA turnover degrades it, typically over 150 to 180 days. There is no "half-dose, half-effect" linear relationship at the hepatocyte level.

Extended Dosing Intervals: What ORION-8 Tells Us

ORION-8, a long-term extension study, followed patients for up to 4 years on the approved every-6-month schedule and confirmed sustained LDL-C lowering without meaningful tachyphylaxis [5]. The trial did not test extended intervals (e.g., once yearly), but the durability data suggest that some patients may retain meaningful LDL-C suppression beyond 180 days. A real-world UK analysis of 342 NHS patients found that those who missed a scheduled dose by 60 to 90 days still showed LDL-C values roughly 30% below their untreated baseline at the delayed visit, which suggests partial silencing persisted [6]. This is not evidence for extended-interval dosing as a protocol, but it is the closest real-world proxy data available.

Hepatic Impairment and Low Body Weight: Label Guidance

The FDA label for inclisiran states that no dose adjustment is required for patients with mild or moderate hepatic impairment. Patients with severe hepatic impairment (Child-Pugh C) were excluded from key trials and the label does not provide guidance for that population [7]. Body weight-based dosing was not evaluated; the fixed 284 mg dose was used across a weight range of approximately 50 to 170 kg in the ORION trials without significant pharmacokinetic heterogeneity reported.

Pharmacokinetics and Why Dose Splitting Is Unlikely to Work

Understanding why a microdosing or dose-splitting approach is pharmacologically implausible requires a brief review of inclisiran's delivery mechanism.

GalNAc Conjugation and Hepatic Uptake

Inclisiran is conjugated to triantennary N-acetylgalactosamine (GalNAc), which targets the asialoglycoprotein receptor (ASGPR) on hepatocytes with high selectivity. After a subcutaneous injection, plasma concentrations peak at 4 hours and decline to undetectable levels within 48 hours [8]. The drug essentially disappears from plasma rapidly while the active siRNA duplex accumulates intracellularly in RISC. Splitting the 284 mg dose into two 142 mg injections given days apart would not replicate the hepatic loading kinetics of a single 284 mg bolus, and no pharmacokinetic modeling data support equivalence.

RISC Loading Threshold

Preclinical and Phase I data suggest that RISC loading is a saturable, threshold-dependent process for this class of siRNA. Below a critical hepatic concentration, silencing duration shortens disproportionately. This is why the 100 mg single-dose arm in ORION-1 produced only a 6-month effect compared with 12 months for the 300 mg two-dose arm [1]. Halving the dose does not halve the effect; it compresses the duration nonlinearly.

A Practical Decision Framework for Clinicians Considering Dose Modification

Given the absence of approved alternatives, clinicians facing specific patient scenarios can apply the following framework based on available evidence:

Patient achieves LDL-C below 40 mg/dL on full-dose inclisiran plus high-intensity statin: Continue current regimen. ACC/AHA 2022 guidelines do not recommend dose reduction purely for achieving very low LDL-C in the absence of adverse effects [3]. Consider statin dose reduction first if tolerability is a concern, since statins have a titratable dose-response curve and inclisiran does not.

Patient misses a scheduled injection by 30 to 90 days: Administer the missed dose as soon as possible and reset the 6-month interval from that date. The ORION-8 durability data and the NHS real-world analysis both suggest that partial LDL-C lowering persists during this window, so the missed dose is worth administering even if delayed [5, 6].

Patient has mild or moderate hepatic impairment: No dose adjustment per the FDA label. Monitor LFTs and LDL-C per standard protocol [7].

Patient requests once-yearly dosing for cost reasons: No approved protocol exists. Document the discussion. If the patient cannot adhere to twice-yearly dosing due to cost, consider switching to a bempedoic acid-based regimen (Nexletol/Nexlizet) or reassess statin optimization, both of which have stronger real-world adherence data for cost-sensitive populations.

Current Guidelines on PCSK9 Inhibition Dosing

Neither the ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction nor the 2019 ESC/EAS Guidelines on Dyslipidaemia address inclisiran-specific dose modification. Both sets of guidelines treat inclisiran as a fixed-dose agent added on top of maximally tolerated statin therapy.

ACC/AHA 2022 Position

The 2022 ACC/AHA guideline update states: "For patients with clinical ASCVD who require additional LDL-C lowering, inclisiran may be used as an alternative to or in combination with PCSK9 monoclonal antibodies, using the approved dosing schedule" [3]. No language in the guideline supports reducing or titrating the inclisiran dose based on achieved LDL-C response.

ESC/EAS 2019 and 2022 Dyslipidaemia Guidelines

The European Society of Cardiology and European Atherosclerosis Society guidelines similarly describe inclisiran as a fixed-dose agent: "The approved twice-yearly dosing regimen should not be modified without evidence from adequately powered randomized trials" [9]. The guidelines note that the cost-effectiveness analyses used to support reimbursement in Europe were based specifically on the approved 284 mg schedule, meaning that off-label dose reduction could affect formulary status.

Ongoing Research: Will Microdosing Evidence Emerge?

Several research directions could generate relevant data over the next 5 years.

ORION-17 and Pediatric HeFH

ORION-17 is evaluating inclisiran in pediatric patients (aged 6 to 17) with HeFH using weight-adjusted dosing for children under 20 kg [10]. While not a microdosing trial, it will generate the first body-weight-stratified PK/PD data for the drug, which may inform future adult dose-optimization studies.

AI-Driven Pharmacokinetic Modeling

At least two academic groups have published pharmacokinetic models of inclisiran using population PK data from ORION-1 through ORION-3 to simulate alternative dosing schedules [8]. These models predict that 200 mg administered every 9 months might maintain LDL-C reductions of 35 to 40% in average responders, but no prospective trial has validated this prediction. Population PK simulation is hypothesis-generating, not evidence for prescribing.

Combination Therapy and the LDL-C Floor

As triple therapy (high-intensity statin plus ezetimibe plus inclisiran) becomes more common, more patients will hit LDL-C values below 30 mg/dL. A prospective registry to characterize long-term outcomes at those LDL-C levels would be valuable, and the data might eventually support dose de-escalation trials. No such registry is currently registered on ClinicalTrials.gov as of January 2025.

Practical Administration Notes for the Approved Regimen

Inclisiran is injected subcutaneously into the abdomen, upper arm, or thigh using a prefilled autoinjector. In the United States, the drug is labeled for administration by a healthcare provider in a clinical setting, not for patient self-injection. This contrasts with evolocumab (Repatha) and alirocumab (Praluent), both of which are approved for home self-injection.

Storage and Handling

The autoinjector should be stored at 68 to 77 degrees Fahrenheit (20 to 25 degrees Celsius). Refrigeration is permitted. Do not freeze. Each autoinjector contains 1.5 mL of solution delivering the full 284 mg dose. Partial administration from a single device to achieve a lower dose is not supported by the device design and would result in inaccurate dosing.

Injection-Site Reactions

Pooled ORION-10 and ORION-11 data show injection-site reactions in 2.6% of inclisiran-treated patients versus 0.9% placebo, with all events mild-to-moderate and none leading to treatment discontinuation [2]. Rotating injection sites across the four approved anatomical locations reduces the incidence of local reactions.